Zymeworks
Biotechnology Research • 
Vancouver, British Columbia, Canada • 201-500 Employees
Company overview
| Headquarters | 114 E 4th Avenue, Suite 800, Vancouver, BC V5T1G4, CA |
| Phone number | +16046781388 |
| Website | |
| NAICS | 541714 |
| SIC | 283 |
| Keywords | Breast Cancer, Antibody Therapeutics, ADC, Protein Engineering, Bispecific Antibodies, Effector Function Modulation, Gastric Cancer, Immune Redirection, Biliary Tract Cancer |
| Founded | 2003 |
| Employees | 201-500 |
| Socials |
Key Contacts at Zymeworks
Kawal Jeet Singh
Executive Director, Head Early Stage Drug Safety
Emily Chen
Associate Director Of Business Development
Derek Miller
Director Board Of Directors, Chair Nomination And Governance Committee, Member Audit Committee
Shrinal Inamdar
Senior Director, Investor Relations
Victor Wong
Associate Director, Corporate Finance
Maggie B. Weinstein
Medical Director
Adam Mott
Senior Director, Quality
Raffaele Colombo
Associate Director, Medicinal Chemistry
Tatenda Aloy Musewe
Associate Director, Legal
David Kroeger
Associate Director Business Development
Zymeworks Email Formats
Zymeworks uses 3 email formats. The most common is {first name}.{last name} (e.g., john.doe@zymeworks.com), used 78.7% of the time.
| Format | Example | Percentage |
|---|---|---|
{first name}.{last name} | john.doe@zymeworks.com | 78.7% |
{first initial}.{last name} | j.doe@zymeworks.com | 19.8% |
{first initial}{last name} | jdoe@zymeworks.com | 1.4% |
About Zymeworks
Zymeworks is a clinical-stage biotechnology company unlocking new possibilities in cancer and autoimmune disease treatment. Our mission is to make a meaningful difference in the lives of patients by advancing a growing pipeline of next-generation antibody therapeutics, including T cell engagers and antibody-drug conjugates (ADCs). Our lead asset, zanidatamab—a HER2-targeted bispecific antibody— is partnered with Jazz Pharmaceuticals and BeOne Medicines and is approved in the U.S. and China for previously-treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer. Zanidatamab is also being evaluated in multiple global clinical trials as a potential best-in-class treatment for patients with multiple HER2-expressing cancers. We’re also rapidly advancing a robust pipeline of wholly-owned ADC and multispecific programs designed to target areas of significant unmet medical need. With integrated R&D capabilities and a proven track record of scientific innovation and collaboration, we’re building strategic partnerships and a culture where passionate people can make an impact. Join us as we engineer what’s next in biotherapeutics.
Zymeworks revenue & valuation
| Annual revenue | $50,500,000 |
| Revenue per employee | $172,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $161,500,000 |
| Total funding | $137,900,000 |
Employees by Management Level
Total employees: 201-500
Seniority
Employees
Employees by Department
Zymeworks has 187 employees across 14 departments.
Departments
Number of employees
Funding Data
Explore Zymeworks's funding history, including investment rounds, total capital raised, and key backers.
Zymeworks Tech Stack
Discover the technologies and tools that power Zymeworks's digital infrastructure, from frameworks to analytics platforms.
Security
Form builders
JavaScript libraries
WordPress themes
Page builders
JavaScript libraries
Font scripts
Databases
JavaScript libraries
Webmail
Programming languages
Switzerland
Netherlands
Frequently asked questions
4.8
40,000 users
